Breaking News
Investing Pro 0
Stocks Are Hot! Get 50% Off InvestingPro Now 🌞 CLAIM OFFER

Insulet Dives After Dexcom Says it is Not in Merger Discussions

Published May 31, 2022 11:50
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
DXCM
-1.77%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PODD
-2.64%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Sam Boughedda

Shares of insulin delivery device maker Insulet (NASDAQ:PODD) have tumbled 12% in early trading Tuesday following a statement from Dexcom (NASDAQ:DXCM) regarding rumors of a potential acquisition of the company.

Last Monday, Bloomberg reported Dexcom was in discussions to acquire Insulet, citing people familiar with the matter.

Dexcom, a company that produces glucose monitoring systems for diabetes management, has now refuted the reports, stating they are not in any discussions regarding a merger.

The company said it regularly reviews opportunities to enhance stockholder value and create benefits for customers, and it does not usually comment on speculation.

However, Dexcom released a statement, stating: "In light of recent sustained media and market speculation as well as the upcoming American Diabetes Association conference, we wish to confirm that Dexcom is not in active discussions regarding a merger transaction at this time."

Insulet shares hit a high of $238.60 in the days following Bloomberg's report but have dropped Tuesday, hitting a low of $199.56. Dexcom stock fell below $270 last week but is trading 6.5% higher in today's session.

Following Dexcom's press release, BTIG analyst Marie Thibault said, "DXCM shares had been pressured in the days following the Bloomberg report while PODD shares have surged. Shares have since reversed in pre-market trading and are near last Monday's close (Dexcom at $324.15 and PODD at $203.12). We expect shares to continue to be volatile in the coming days as investors digest this release ahead of this upcoming weekend's American Diabetes Association 82nd Scientific Sessions."

The analyst reiterated a Buy rating and a $540 price target on Dexcom.

Oppenheimer's Steven Lichtman is not surprised by the news, saying they questioned the fit. They see the companies benefiting from their connection through Omnipod 5 without having to be under one roof. Lichtman rates Dexcom at Outperform with a $525 target.

Insulet Dives After Dexcom Says it is Not in Merger Discussions
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email